{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"38"}],"units":"Participants"}],"description":"Dose reductions were not permitted for trilaciclib, per study protocol. Dose reductions for E/P were derived from changes in the protocol-specified dose on the dosing page and corresponded to the reductions for toxicity specified in the protocol. No more than 2 dose reductions of E/P in total were allowed for any participant. Simultaneous reductions in the doses of E/P were counted as 1 dose reduction. For the treatment period, the total number of dose reductions was the number of cycles where there was at least 1 dose reduction.","groups":[{"description":"Participants received placebo IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG000","title":"Part 2: Placebo"},{"description":"Participants received trilaciclib 240 mg/m\\^2 IV once daily on Days 1 to 3 of each 21-day E/P chemotherapy cycle.","id":"OG001","title":"Part 2: Trilaciclib 240 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety analysis set - included all enrolled participants (i.e., signed informed consent) who received at least 1 dose of study drug (etoposide, carboplatin, or trilaciclib).\n\nPart 1: Cohort 1 Trilaciclib 200 mg/m\\^2 included 1 participant from Part 2 and 1 participant from Part 1 240 mg/m\\^2 who received 200 mg/m\\^2.","reportingStatus":"POSTED","timeFrame":"From randomization to the end of the treatment period (a minimum of 51 days up to a maximum of 379 days)","title":"Occurrence of Dose Reduction in Part 2","type":"SECONDARY","unitOfMeasure":"Participants"}